Status:
COMPLETED
Immunogenicity of HPV Vaccine in Immunosuppressed Children
Lead Sponsor:
The University of New South Wales
Collaborating Sponsors:
Sydney Children's Hospitals Network
Women's and Children's Hospital, Australia
Conditions:
Autoimmune Disease
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
5-18 years
Phase:
PHASE3
Brief Summary
Genital HPV is the necessary cause for cervical cancer, as well as a major contributing cause of several other cancers and conditions. There are now effective vaccines against the main oncogenic HPV t...
Detailed Description
To determine the immunogenicity, safety and persistence of immunity following human papillomavirus (HPV) vaccination in three groups of immunosuppressed children: recipients of allogenic bone marrow t...
Eligibility Criteria
Inclusion
- \- Immunosuppressed patients with following diseases; Bone marrow transplant recipients, liver transplant patients, renal transplant, Children with inflammatory bowel disease, juvenile Idiopathic arthritis and autoimmune conditions.
Exclusion
- A platelet count of \<50
- Immunoglobulin therapy within 3 months.
- Yeast allergy
- Any other known allergies to one of the vaccine component
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT02263703
Start Date
May 1 2007
End Date
December 1 2016
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Public Health and Community Medicine
Sydney, New South Wales, Australia, 2052